Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced its participation in the Jefferies Global Healthcare Conference. Steven Kelly, President and CEO, will join a fireside chat on June 6, 2024, at 3:00 pm ET. An audio webcast will be available on the Investor Events section of the company's website and archived for a time.
Positive
- Participation in a prestigious event like the Jefferies Global Healthcare Conference can enhance Carisma Therapeutics' visibility among investors and stakeholders.
- The involvement of Steven Kelly, the CEO, in the fireside chat may provide valuable insights into the company's future plans and strategic direction.
Negative
- The press release does not provide specific updates on the company's financial performance, clinical trial progress, or any new business developments, limiting the information for investors seeking detailed updates.
- The announcement of an audio webcast being archived for a time may not be sufficient for all investors, particularly those who may miss the live event or the archive window.
News Market Reaction – CARM
In the trading session that priced this news, CARM gained 1.55%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-302158376.html
SOURCE Carisma Therapeutics Inc.